Twareat turns to SAR 10.3M loss in 2025, SAR 15.9M in H2

Twareat Medical Care Co. swung to a net loss of SAR 10.3 million in 2025, compared to a net profit of SAR 23.5 in 2024.

The company attributed the losses mainly to expected credit losses (ECL) of SAR 14.8 million, resulting from fully provisioning receivables due from Saudi Basic Industries Corp. (SABIC) following a legal dispute.

Revenue was also impacted by the reduction in the scope of the industrial clinics’ operation contract with SABIC at the end of 2024, prior to its final termination in September 2025. Despite this, the company mitigated most of the decline by improving its sales strategy, signing new service contracts across different regions of the Kingdom, and expanding medical services to existing clients.

The period also reflected the conclusion of the SABIC clinics contract, although the company offset much of the impact through enhanced sales performance, strategic new contracts, and competitive service margins while investments continued in new business lines, including the first-aid factory, medical transport services, and the training center, which are expected to contribute positively in upcoming periods.

In H2 2025, Twareat swung to a net loss of SAR 15.9 million against a net profit of SAR 7.39 million in a prior-year period.

Compared with H1 2025, the company also moved into net losses from a net profit of SAR 5.53 million.

Shareholders’ equity, after minority interest, decreased to SAR 46.64 million as of Dec. 31, 2025, from SAR 67.23 million a year earlier.

View More Financial Results